Evista (raloxifene) can help prevent breast cancer in postmenopausal women with osteoporosis
February 2005
There's growing evidence that Evista (raloxifene) can help prevent breast cancer in postmenopausal women with osteoporosis.
Evista is approved only to prevent or treat osteoporosis in postmenopausal women. But Evista might lead to a 60% reduction in breast cancer.
It's too soon to prescribe Evista to prevent breast cancer. Continue to use Evista for women who need treatment for osteoporosis...and consider breast cancer prevention a possible beneficial side effect.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote